These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 27166877)

  • 1. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
    Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
    Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
    Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
    BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A polypeptide from the junction region sequence of EWS-FLI1 inhibits Ewing's sarcoma cells, interacts with the EWS-FLI1 and partner proteins.
    Thangaretnam KP; Gopisetty G; Ramanathan P; Rajkumar T
    Sci Rep; 2017 Aug; 7(1):7172. PubMed ID: 28775288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
    Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
    Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.
    Ban J; Jug G; Mestdagh P; Schwentner R; Kauer M; Aryee DN; Schaefer KL; Nakatani F; Scotlandi K; Reiter M; Strunk D; Speleman F; Vandesompele J; Kovar H
    Oncogene; 2011 May; 30(18):2173-80. PubMed ID: 21217773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.
    Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA
    Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
    Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
    Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
    Uren A; Toretsky JA
    Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
    Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
    Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
    Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
    J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.
    Sengupta A; Rahman M; Mateo-Lozano S; Tirado OM; Notario V
    Int J Oncol; 2013 Sep; 43(3):803-12. PubMed ID: 23857410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
    He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
    Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo.
    Aryee DN; Kreppel M; Bachmaier R; Uren A; Muehlbacher K; Wagner S; Breiteneder H; Ban J; Toretsky JA; Kovar H
    Cancer Res; 2006 Oct; 66(20):9862-9. PubMed ID: 17047047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
    Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
    Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
    Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C
    Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
    Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
    Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma.
    Toub N; Bertrand JR; Tamaddon A; Elhamess H; Hillaireau H; Maksimenko A; Maccario J; Malvy C; Fattal E; Couvreur P
    Pharm Res; 2006 May; 23(5):892-900. PubMed ID: 16715379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
    Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
    Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for DAX1/EWS-FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma.
    Watanabe M; Kosaka H; Sugawara M; Maemoto M; Ono Y; Uemori T; Shizu R; Yoshinari K
    Cancer Med; 2023 Apr; 12(8):9802-9814. PubMed ID: 36825574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.